CLSD Clearside Biomedical, Inc.

+0  (1%)
Previous Close 7.55
Open 7.58
Price To book 2.59
Market Cap 193.44M
Shares 25,286,000
Volume 85,404
Short Ratio 3.52
Av. Daily Volume 192,542

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated mid-2017.
Suprachoroidal CLS-TA - TYBEE
Diabetic Macula Edema (DME)
Phase 1/2 enrollment completion announced April 20, 2017. Preliminary data due 2H 2017.
Suprachoroidal CLS-TA - HULK
Diabetic macular edema (DME)
Announced enrollment of the first patient in its Phase 3 trial - February 16, 2017.
Suprachoroidal CLS-TA - SAPPHIRE
Macular edema associated with retinal vein occlusion (RVO)
Phase 3 data preliminary data due early 2018.
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
Phase 1/2 trial to be initiated following IND submission late 2016.
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema
  2. Edited Transcript of CLSD earnings conference call or presentation 14-Mar-17 12:30pm GMT
  3. Clearside Biomedical Enters into Strategic Collaboration with EyeKor to Support Clinical Development Efforts
  4. Clearside Biomedical, Inc. to Present at the 16th Annual Needham Healthcare Conference
  5. Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results
  6. Clearside Biomedical, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017 – Conference Call to Follow
  7. Clearside Biomedical, Inc. to Present at the Cowen and Company 37th Annual Health Care Conference
  8. Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent
  9. Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program
  10. Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
  11. Clearside BioMedical (CLSD) is Oversold: Can It Recover?
  12. How Clearside (CLSD) Stock Stands Out in a Strong Industry
  13. Clearside Biomedical Closes in on Secondary Offering
  14. Clearside Biomedical Prices Secondary Offering
  15. ETFs with exposure to Clearside Biomedical, Inc. : December 1, 2016